As of 6 Nov 2026, Jeevan Scientific Technology trades at 28.3× trailing earnings, below the industry P/E of 52.8×, and the shares are 14% below their 52-week high. Sales grew 19% a year over 3 years; its ROCE of 4.7% is the lowest among the 7 largest Diagnostics & Research peers. Debt is 0.29× equity. It is a small-cap company with a market cap of ₹161 Cr, ranked 11th of 18 Diagnostics & Research companies by market cap; the shares rose 29% over the past year.
- ₹86.00
- ₹86.00
- ₹80.00
- ₹80.63
- 7K
Health check
- ReturnsAhead
+29.0% over a year, better than 5 of 7 peers.
- Price tagCheaper
P/E 28.3 vs industry 52.8.
- GrowthStrong
Sales +19.4% a year over 3 years.
- ProfitabilityWeak
ROCE 4.7% vs peer median 19.1%.
- Balance sheetFair
Debt 0.29× equity, interest covered 2.1×, Piotroski 6 of 9.
- Red flags1 to check
Return on equity is low at 1.9%.
Small cap
Defensive
Key metrics
- Market cap
- ₹161 Cr
- Small cap
- P/E
- 28.3
- Industry 52.8
- Price to book
- 1.96
- Peers 11.99
- Dividend yield
- 0.00%
- ROE
- 1.9%
- Peers 17.7%
- ROCE
- 4.7%
- Peers 19.1%
- Debt to equity
- 0.29
- Debt ₹21 Cr
- EPS (TTM)
- ₹2.86
- OPM (TTM)
- 20.5%
- Net margin 6.8%
- Sales growth
- +81.7%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 2.27
- EV/EBITDA 7.7
Strengths and risks
Strengths
- Quarterly sales up 81.7% on a year ago.
- P/E of 28.3 against an industry P/E of 52.8.
Risks to check
- Return on equity is low at 1.9%.
About Jeevan Scientific Technology
Jeevan Scientific Technology Limited engages in the clinical research and data management businesses in India. The company's services include BA/BE studies that comprise bioanalytical and clinical services, pharmacokinetic and biostatistics, and glucose clamping; clinical trial services, such as medical writing, clinical trial management and monitoring, drug safety, clinical data management, biostatistics and statistical programming, and quality…
- Headquarters
- Hyderabad
- Employees
- 285
- Sector
- Healthcare
- ISIN
- INE237B01018
- Website
- jeevanscientific.com
Price range
- Avg volume (3M)
- 31.9K
- 1-year return
- plus 29.0%
- From 52-week high
- minus 13.9%
Peers · Diagnostics & Research
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAILIFESai Life Sciences | 1,785.10 | plus 11.95% | 37,929 | 101.5 | 15.22 | 18.1% | 15.1% | 28.7% | 21.3% | 226.8% | 0.00% | plus 72.7% |
| LALPATHLABDr. Lal Path Labs | 1,970.00 | plus 0.16% | 32,941 | 56.5 | 11.99 | 25.7% | 22.6% | 30.2% | 11.1% | 28.3% | 1.02% | plus 24.7% |
| SYNGENESyngene International | 417.30 | plus 0.77% | 16,772 | 90.3 | 3.46 | 8.3% | 3.9% | 25.7% | 5.4% | −12.0% | 0.30% | minus 36.0% |
| VIJAYAVijaya Diagnostic Centre | 1,468.60 | plus 2.15% | 15,126 | 74.4 | 14.29 | 19.1% | 21.2% | 43.1% | 21.0% | 26.9% | 0.14% | plus 40.2% |
| METROPOLISMetropolis Healthcare | 568.75 | minus 0.39% | 11,803 | 52.8 | 7.17 | 15.7% | 14.6% | 21.7% | 12.7% | 10.0% | 0.35% | plus 12.5% |
| THYROCAREThyrocare Technologies | 493.10 | plus 0.68% | 7,848 | 55.0 | 14.75 | 33.8% | 26.4% | 32.2% | 16.7% | 36.2% | 1.89% | plus 8.3% |
| VIMTALABSVimta Labs | 496.45 | minus 2.14% | 2,219 | 27.9 | 4.52 | 21.0% | 17.7% | 34.7% | 8.9% | 17.2% | 0.40% | minus 23.3% |
| JSTLJeevan Scientific Technology | 80.87 | plus 0.30% | 161 | 28.3 | 1.96 | 4.7% | 1.9% | 20.5% | 19.4% | – | 0.00% | plus 29.0% |
| Median of 7 peers | – | 0.68% | 15,126 | 56.5 | 11.99 | 19.1% | 17.7% | 30.2% | 12.7% | 26.9% | 0.35% | 12.5% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 10.1 | 12.4 | 19.1 | 21.3 | 18.3 | |
| 10.4 | 10.3 | 13.8 | 17 | 15.3 | |
| −0.4 | 2.1 | 5.2 | 4.3 | 3 | |
| −3.8% | 16.7% | 27.4% | 20.2% | 16.2% | |
| 0.1 | 0.2 | 0.1 | 0.3 | 0.2 | |
| 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | |
| 1.8 | 1.7 | 1.6 | 1.6 | 1.7 | |
| −2.6 | 0 | 3.2 | 2.6 | 1 | |
| 50.6% | 68.2% | 25.6% | 28.2% | 10.9% | |
| −1.3 | −0.1 | 1.4 | 1.6 | 0.5 | |
| -0.81 | -0.01 | 1.52 | 0.92 | 0.43 |
Profit & loss
- Sales CAGR 3Y
- +19.4%
- ROE
- 1.9%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 36.2 | 39.7 | 46.8 | 61.5 | |
| – | +9.6% | +18.1% | +31.4% | |
| 34.8 | 35 | 39.3 | 51.5 | |
| 1.4 | 4.7 | 7.6 | 10 | |
| 3.8% | 11.8% | 16.2% | 16.3% | |
| 1 | 0.5 | −0.4 | 0.7 | |
| 1 | 0.9 | 1 | 1.9 | |
| 5.1 | 5.9 | 6.3 | 6.6 | |
| – | −0 | 0.1 | 0 | |
| −3.7 | −1.6 | 0.1 | 2.1 | |
| 16.8% | 17.3% | −16.4% | 50.6% | |
| −3 | −1.3 | 0.1 | 1.2 | |
| -1.99 | -0.84 | 0.09 | 0.68 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 15.5 | 15.5 | 15.8 | 19.9 | |
| 32.7 | 32.9 | 34 | 51.8 | |
| 10.1 | 13.4 | 20.6 | 21.3 | |
| 7.6 | 6 | 7.9 | 13.6 | |
| 65.9 | 67.9 | 78.3 | 107 | |
| 29.4 | 36 | 41 | 45.8 | |
| 10.5 | 14.9 | 13.3 | 16.8 | |
| 0 | 0 | 0 | 3 | |
| 6.8 | 0.5 | 0.2 | 9.5 | |
| 19.2 | 16.4 | 23.8 | 31.5 | |
| 65.9 | 67.9 | 78.3 | 107 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −6.4 | 2.9 | 10.1 | 0.4 | |
| −6.9 | −11.5 | −15.6 | −10 | |
| −9.5 | 2.3 | 5.2 | 18.8 | |
| −22.9 | −6.3 | −0.3 | 9.3 | |
| −8.2 | −12 | −16 | −8.2 | |
| −14.6 | −9.1 | −6 | −7.8 | |
| −1.8 | – | – | – |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.